New supply arrangements for haemophilia care
Thursday 12th May 2005
PHARMAC develops new supply arrangements for haemophilia care
Government drug purchasing agency PHARMAC has developed a programme for purchasing haemophilia treatment products which should enable continuous supply whilst making significant cost efficiencies.
The Haemophilia Foundation of New Zealand (HFNZ) is confident that PHARMAC’s proposal offers a secure supply. President Dave McCone said, “Because our members are so utterly dependent on regular and safe treatment, we have been worried for some time by PHARMAC’s preference for sole suppliers.
We are relieved that PHARMAC has taken our concerns seriously, and has come up with a solution that ticks all the right boxes: product safety, surety of supply and cost-efficiency. We also welcome a national purchasing agreement, which is a meaningful step towards optimizing the available resources and making high quality care available nationally.”
PHARMAC’s proposal invites three pharmaceutical suppliers to participate in a programme for national supply of recombinant Factor VIII through to June 2008.